The role of mTOR signaling in cancer cells
Project/Area Number |
15K19015
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
General medical chemistry
|
Research Institution | Aichi Cancer Center Research Institute (2016-2017) Kitasato University (2015) |
Principal Investigator |
Sato Tatsuhiro 愛知県がんセンター(研究所), 分子腫瘍学部, 主任研究員 (70547893)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | Rheb / mTOR / mTORC1 / SmgGDS / CAD / ヌクレオチド生合成 / filamin A |
Outline of Final Research Achievements |
In this study, the role of Rheb-mTOR signaling pathway in tumor development and malignancy was analyzed. We found that Rheb binds and activates CAD, leading to increased nucleotide pool that is required for DNA replication. Moreover, filamin A was found to be phosphorylated by mTOR complex 2 to regulates the migration in melanoma cells. We also revealed SmgGDS as a regulator of Rheb-mTOR signaling pathway and MTOR gene mutations, that activates mTOR complex 1, in breast cancer and renal cell carcinoma. These findings is suggested to contribute to elucidating the molecular mechanism by which mTOR signaling promotes tumor formation.
|
Report
(4 results)
Research Products
(8 results)